Article Text

Download PDFPDF

2022-RA-576-ESGO Expression VIII – first study of individual perception and level of information of patients with low grade ovarian cancer and borderline tumor of the ovary in 321 patients
  1. Laura Naomi Beckmann1,
  2. Sara Alavi1,
  3. Maren Keller2,
  4. Clemens Liebrich3,
  5. Karol Kubiak4,
  6. Pauline Wimberger5,
  7. Vera Czolk6,
  8. Anette Ligl-Löhner7,
  9. Hans-Martin Enzinger8,
  10. Aline Burdack9,
  11. Dorothea Fischer10,
  12. Jürgen Terhaag11,
  13. Cornelia Müller12,
  14. Volker Hanf13,
  15. Mateja Condic14,
  16. Georg Kunz15,
  17. Tilmann Lantzsch16,
  18. Ute Schilling17,
  19. Gülten Oskay-Özcelik1 and
  20. Jalid Sehouli1
  1. 1Department of Gynecology with Center for Oncological Surgery, European Compe-tence Center for Ovarian Cancer, Charité – Campus Virchow-Klinikum, University Medicine of Berlin, Berlin, Germany
  2. 2North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin, Germany
  3. 3Gynäkologisches Krebszentrum, Klinikum Wolfsburg, Wolfsburg, Germany
  4. 4St. Franziskus-Hospital GmbH, Münster, Germany
  5. 5Department of Gynecology and Obstetrics, TU Dresden Medizinische Fakultat Carl Gustav Carus, Dresden, Germany
  6. 6Diako Mannheim, Mannheim, Germany
  7. 7Diakonissen-Stiftung-Krankenhaus Speyer, Speyer, Germany
  8. 8Sozialstiftung Bamberg, Bamberg, Germany
  9. 9Sana Klinikum Lichtenberg, Berlin, Germany
  10. 10Klinikum Ernst von Bergmann gemeinnützige GmbH, Potsdam, Germany
  11. 11Rottal-Inn Kliniken KU Eggenfelden, Eggenfelden, Germany
  12. 12Universitätklinikum Brandenburg an der Havel, Brandenburg an der Havel, Germany
  13. 13Klinikum Fürth, Fürth, Germany
  14. 14Universitätsklinikum Bonn, Bonn, Germany
  15. 15St.-Johannes-Hospital Dortmund, Dortmund, Germany
  16. 16Krankenhaus St. Elisabeth und St. Barbara Halle (Saale) GmbH, Halle (Saale), Germany
  17. 17Park-Klinik Weißensee, Berlin, Germany


Introduction/Background Low-grade serous carcinomas (LGSC) are associated with better prognoses compared to their high-grade serous (HGSC) counterparts. Nevertheless, we are confronted with a challenging treatment, since the median age upon diagnosis is younger, standard platinum-based chemotherapy is less effective and, most importantly, it has still not been as well studied as HGSC. The purpose of this ongoing study was to examine patients’ perception and assessment regarding their disease and therapy as well as the level of information among women with LGSC and borderline ovarian tumors (BOT).

Methodology A questionnaire was developed based on the experiences of previous EXPRESSION-trials and provided to patients with LGSC and BOT. The hardcopy-version was converted into an online database and statistically analyzed via SPSS-Software.

Results From March 2019, 321 patients with LGSC and BOT from eighteen German clinics and gynecological practices participated in the survey, 90 (28%) with LGSC and 231 (72%) with BOT. While nearly all patients (97.8% LGSC; 94.3% BOT) had primary surgery, 58% of LGSC patients received adjuvant chemotherapy. Patients indicated the attending physician as the main source of information (81% LGSC; 85% BOT). The majority were pleased with the explanation about their illness and therapy. Significantly more BOT-patients were not aware of their tumor stage during initial diagnosis (31.4% LGSC vs 64.5% BOT, p= <0.0001). 47.8% of LGSC-patients did not know the difference between LGSC and HGSC and 73.9% were not offered a hormone replacement therapy. BOT-patients estimate the aggressiveness (31.2% BOT vs. 52.2% LGSC) and the risk of recurrence (28.2% BOT vs. 44% LGSC) of their disease lower than LGSC-patients.

Conclusion This study underlines the high need for more detailed explanation in this specific patient group with a greater focus on the underlying tumor biology and the corresponding course of disease and prognosis.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.